Biokin Pharmaceutical Co. Ltd. has selected Cryoport’s full suite of temperature-controlled solutions to support its Phase I and II clinical trials in immuno-oncology in both the US and China.

Biokin Pharma, a biopharmaceutical company based in China, focuses on the treatment of cancer through developing novel therapeutic antibodies and antibody-drug conjugates.

The company utilises several technology platforms to develop advanced antibody-based drug therapies, it’s wholly-owned subsidiary Systimmune Inc., was formed to advance its mission in the US.

Partnering with Cryoport will enable Biokin Pharma and Systimmune to utilise Cryoport’s full range of temperature-controlled logistics solutions to support its drug manufacturing processes across the globe. These solutions include Cryoport Express® shippers, the Cryoportal™ Logistics Management Platform, Smartpak II™ Condition Monitoring System and logistics support.

“We are pleased to choose the highly reliable condition- and time-sensitive logistics solutions provided by Cryoport to support our upcoming clinical studies using Bispecific and Multi-specific Antibody, ADC, and T-cell Therapy,” said Dr. Yi Zhu, Chairman of Biokin Pharma and its US subsidiary, Systimmune of Seattle, WA.

“By relying on Cryoport’s excellent solutions, Biokin Pharma and Systimmune will continue to have the best possible viability and recovery of critical cells, vectors, antibodies and other materials, even after time-consuming international or domestic transportation, to ensure the best outcome for our patients,” Dr. Yi Zhu continued.

“As the regenerative medicine market rapidly matures, the demand for our technology driven solutions to support trials across the globe is growing. We look forward to working alongside Biokin Pharma and its US subsidiary to ensure reliable, secure logistics support for their temperature-sensitive commodities as they advance the development of potentially life-saving therapies,” said Mark Sawicki, PhD, Chief Commercial Officer of Cryoport.